Fred Hirsch Hirsch
About Fred Hirsch Hirsch
Fred Hirsch is a Professor at the University of Colorado, specializing in biomarker development for lung cancer treatment and early detection. He co-chairs the Lung Group for translational science within the Southwest Oncology Group and leads a lab focused on personalized medicine.
Work at University of Colorado
Fred Hirsch has been a Professor at the University of Colorado since 2000. His tenure spans 24 years in Denver, Colorado, where he focuses on advancing research in lung cancer. His role involves leading initiatives in biomarker development and validation, which are crucial for improving treatment and early detection of lung cancer. Hirsch also serves as the principal investigator for various clinical trials, contributing to the university's reputation in cancer research.
Education and Expertise
Fred Hirsch possesses a dual training background in medical oncology and pathology. This extensive education underpins his expertise in lung cancer research and treatment. His focus on biomarker development and validation positions him as a key figure in the field, particularly in personalized medicine and targeted therapies for lung cancer patients.
Background
Prior to his current role, Fred Hirsch worked at Rigshospitalet in Copenhagen, Denmark, from 1977 to 2000. During his 23 years there, he served as a Staff Physician and Associate Professor. This experience contributed to his foundational knowledge and skills in oncology, which he has applied throughout his career in the United States.
Achievements in Lung Cancer Research
Fred Hirsch co-chairs the Lung Group for translational science within the Southwest Oncology Group (SWOG). He acts as the study chair for correlative science in the Lung Masterprotocol (LungMAP), which emphasizes his leadership in lung cancer research initiatives. His role as a principal investigator in numerous clinical trials further highlights his commitment to advancing treatment options in this field.
Leadership in International Lung Cancer Community
Fred Hirsch holds the position of CEO/Executive Director for the International Association for the Study of Lung Cancer (IASLC). This organization includes members from over 80 countries, reflecting his influence and leadership in the global lung cancer research community. His role involves fostering collaboration and sharing knowledge among professionals dedicated to lung cancer research and treatment.